BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04693351 (Troriluzule in Obsessive Compulsive Disorder): BVCT ex-ante prediction vs. reported outcome

On 6 Mar 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 11 Aug 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04693351
Drug Name
Troriluzule
Drug MoA
riluzole prodrug
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Mental Disorders
Indication
Obsessive Compulsive Disorder
Human Patients
589
Sponsor
Biohaven Pharmaceuticals
Phase
Phase 3

Prediction of , index 1499

Prospective Prediction
Prediction Index
1499
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
523 days in advance
Readout Data Interpretation
troriluzole failed to achieve the efficacy primary endpoint
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Phase
Phase 3
Status
Completed
Enrollment
589
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG: Troriluzole; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-01-29
Primary completion
2025-04-29
Completion
2025-04-29
Results first posted
2026-05-22
Primary outcomes
  • Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement) (Baseline and Week 8)

NCT04693351 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials